A case of recurrent immunotactoid glomerulopathy in an allograft treated with rituximab

Transplantation Proceedings
S SathyanK V Ranga

Abstract

Immunotactoid glomerulopathy is a glomerular disorder typified by hollow cylindrical and sometimes spherical microtubular deposits, with a diameter of 30-40 nm, but up to 90 nm, often in a parallel arrangement or in intersecting bundles. These patients frequently end up receiving kidney transplants due to progressive renal insufficiency. Known to recur in renal transplant recipients with variable outcomes, its treatment options are limited. Classically steroids, cyclophosphamide, mycophenolate mofetil, and plasma exchanges have been used to treat these recurrences. More recently, rituximab has been suggested as a treatment and has demonstrated improved outcomes in other glomerular diseases. Herein we describe a case of a middle-aged female renal transplant recipient for end-stage renal disease secondary to immunotactoid glomerulopathy, who experienced a recurrence of this condition in the transplanted kidney. Following a failure of conventional therapy we administered a course of rituximab, resulting in a reduction and stabilization of her serum creatinine level while her proteinuria persisted.

References

Feb 1, 1992·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·C E Alpers
Oct 1, 1980·Ultrastructural Pathology·M M Schwartz, E J Lewis
Sep 1, 1993·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·A FogoR G Horn
Jun 1, 2000·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·X CarlesD Durand
Oct 2, 2002·Lancet·Giuseppe RemuzziPiero Ruggenenti
Jun 24, 2003·Journal of the American Society of Nephrology : JASN·Piero RuggenentiGiuseppe Remuzzi
Jan 8, 2004·Ultrastructural Pathology·David N HowellGuillermo A Herrera

❮ Previous
Next ❯

Citations

Mar 2, 2012·MAbs·A Ahsan EjazNasimul Ahsan
Jul 16, 2016·Clinical Journal of the American Society of Nephrology : CJASN·Jonathan J Hogan, Brendan M Weiss
Jul 20, 2010·Current Opinion in Nephrology and Hypertension·Todd Fairhead, Greg Knoll
Mar 28, 2012·Transplantation·Jamila Rasouli-ArsalaJohn C Papadimitriou
Aug 24, 2017·Current Opinion in Nephrology and Hypertension·Christopher D Blosser, Roy D Bloom
Sep 3, 2019·Frontiers in Immunology·Wai H LimGermaine Wong
Aug 21, 2020·Kidney International·Samih H NasrGlen S Markowitz
Dec 29, 2020·American Journal of Therapeutics·Edin AdilovicAaron Dommu
Oct 26, 2020·Hematology/oncology Clinics of North America·Sascha A Tuchman, Jeffrey A Zonder
Apr 8, 2021·Nefrología : publicación oficial de la Sociedad Española Nefrologia·Juana Alonso-TitosDomingo Hernández

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.